Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.
作者信息
Mian Maha N, Dinh Michael T, Coker Allison R, Mitchell Jennifer M, Anderson Brian T
机构信息
Department of Psychology, Suffolk University, Boston, Mass. (Mian); Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco (Mian, Dinh, Mitchell, Anderson); Kaiser Permanente Northern California, Division of Research, Oakland, Calif. (Mian); Department of Psychology, Suffolk University, Boston (Mian); Department of Neurology, University of California San Francisco, San Francisco (Coker, Mitchell); Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, Calif. (Coker); Department of Veterans Affairs, Research Service, San Francisco VA Medical Center, San Francisco (Mitchell); UC Berkeley Center for the Science of Psychedelics, Berkeley, Calif. (Mitchell, Anderson).
出版信息
Am J Psychiatry. 2025 Jan 1;182(1):6-9. doi: 10.1176/appi.ajp.20230787.
Abstract
摘要
相似文献
1
Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options.《超越<管制物质法>的迷幻药监管：描述政策选项的三维框架》
Am J Psychiatry. 2025 Jan 1;182(1):6-9. doi: 10.1176/appi.ajp.20230787.
2
Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.使用迷幻剂者对迷幻剂政策和实践的偏好和支持。
J Psychoactive Drugs. 2023 Nov-Dec;55(5):650-659. doi: 10.1080/02791072.2023.2228784. Epub 2023 Jun 23.
3
Psychedelic-Assisted Therapy: Emerging Treatments in Mental Health Disorders.迷幻辅助治疗：精神障碍治疗的新方法。
Am J Nurs. 2021 Jun 1;121(6):34-40. doi: 10.1097/01.NAJ.0000753464.35523.29.
4
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.新型药物申请和《受控物质法》分类的致幻药物滥用潜力评估研究。
Neuropharmacology. 2022 Nov 1;218:109220. doi: 10.1016/j.neuropharm.2022.109220. Epub 2022 Aug 17.
5
A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.一项关于临终时心理痛苦的迷幻剂干预措施差异的范围综述方案。
PLoS One. 2025 May 6;20(5):e0318343. doi: 10.1371/journal.pone.0318343. eCollection 2025.
6
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.与澳大利亚迷幻辅助治疗相关的监管和政策问题分类。
Aust N Z J Psychiatry. 2024 Jul;58(7):571-590. doi: 10.1177/00048674241240597. Epub 2024 Apr 16.
7
Co-use of psychedelics with other substances: Findings from the global psychedelic survey.迷幻剂与其他物质的共同使用：全球迷幻剂调查结果
J Psychopharmacol. 2025 May;39(5):453-462. doi: 10.1177/02698811241292956. Epub 2024 Oct 28.
8
Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.迈向迷幻学徒制：发展一种温和的方法来调解和验证迷幻引起的洞察和启示。
Transcult Psychiatry. 2022 Oct;59(5):691-704. doi: 10.1177/13634615221082796. Epub 2022 Mar 22.
9
Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey.天然和合成迷幻物质的偏好、认知及环境考量：全球迷幻调查结果
J Psychoactive Drugs. 2024 Dec 24:1-11. doi: 10.1080/02791072.2024.2446445.
10
The Psychedelic Renaissance and Its Forensic Implications.迷幻复兴及其法医学意义。
J Am Acad Psychiatry Law. 2020 Mar;48(1):87-97. doi: 10.29158/JAAPL.003917-20. Epub 2020 Jan 16.
引用本文的文献
1
Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.裸盖菇素作为慢性疼痛康复中的一种心理生理适应原。
J Pain. 2025 Jul 21:105507. doi: 10.1016/j.jpain.2025.105507.
本文引用的文献
1
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.MDMA 辅助治疗中重度 PTSD：一项随机、安慰剂对照的 3 期试验。
Nat Med. 2023 Oct;29(10):2473-2480. doi: 10.1038/s41591-023-02565-4. Epub 2023 Sep 14.
2
Psychedelic Drug Legislative Reform and Legalization in the US.美国迷幻药立法改革与合法化。
JAMA Psychiatry. 2023 Jan 1;80(1):77-83. doi: 10.1001/jamapsychiatry.2022.4101.
3
Applying Lessons From Cannabis to the Psychedelic Highway: Buckle Up and Build Infrastructure.将大麻的经验教训应用于迷幻药发展之路：系好安全带，构建基础设施。
JAMA Health Forum. 2022 Jun 3;3(6):e221618. doi: 10.1001/jamahealthforum.2022.1618.
4
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.新型药物申请和《受控物质法》分类的致幻药物滥用潜力评估研究。
Neuropharmacology. 2022 Nov 1;218:109220. doi: 10.1016/j.neuropharm.2022.109220. Epub 2022 Aug 17.
5
Ancient psychoactive plants in a global village: The ritual use of cannabis in a self-managed community in Catalonia.全球化村落中的古代致幻植物：加泰罗尼亚自治社区中的大麻仪式性使用。
Int J Drug Policy. 2021 Dec;98:103390. doi: 10.1016/j.drugpo.2021.103390. Epub 2021 Jul 30.
6
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.经典致幻剂/迷幻剂在治疗环境中的应用：医疗保健政策机遇与挑战
Risk Manag Healthc Policy. 2021 Mar 5;14:901-910. doi: 10.2147/RMHP.S300656. eCollection 2021.
7
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.迷幻蘑菇辅助治疗对重度抑郁症的影响：一项随机临床试验。
JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285.
8
Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.精神活性药物治疗创伤后应激障碍的疗效：3,4－亚甲基二氧甲基苯丙胺、氯胺酮、麦角酸二乙胺和裸盖菇素的系统评价
J Psychoactive Drugs. 2021 Jan-Mar;53(1):85-95. doi: 10.1080/02791072.2020.1817639. Epub 2020 Sep 15.
9
Psychedelics and the essential importance of context.迷幻剂与语境的重要性
J Psychopharmacol. 2018 Jul;32(7):725-731. doi: 10.1177/0269881118754710. Epub 2018 Feb 15.
10
Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting.药用大麻：历史、药理学及其在急性护理环境中的意义
P T. 2017 Mar;42(3):180-188.
Zotero 插件